Click to search for your profile
Click to search for condition or expert
Click to open main menu
Save Condition
Bookmark
Share
Share
Condition
Clinical Trials for
Essential Thrombocythemia
Overview
Find a Doctor
Latest Advances
Clinical Trials
Clinical Trials
Search for trials
Filter
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
60
Start Date:
May 2021
A Phase 2 Study Of Ruxolitinib In Low-Risk Essential Thrombocythemia And Polycythemia Vera With Significant Symptom Burden
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
73
Start Date:
March 31, 2021
A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy
Search for trials
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1
Intervention Type:
Other, Biological
Participants:
15
Start Date:
March 1, 2021
A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With Myelofibrosis
Clinical Trial
Status:
Recruiting
Phase:
Phase 3
Intervention Type:
Drug
Participants:
320
Start Date:
January 2021
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug
Participants:
24
Start Date:
January 1, 2021
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Clinical Trial
Status:
Recruiting
Phase:
Phase 1
Intervention Type:
Drug
Participants:
15
Start Date:
December 31, 2020
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis
Clinical Trial
Status:
Recruiting
Phase:
Phase 1
Intervention Type:
Drug
Participants:
90
Start Date:
December 21, 2020
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug
Participants:
60
Start Date:
December 8, 2020
Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug
Participants:
78
Start Date:
December 2020
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
24
Start Date:
October 2, 2020
Investigator-Initiated Trial of the LSD1 Inhibitor IMG-7289 for the Treatment of Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) That Have Failed at Least One Standard Therapy
Clinical Trial
Status:
Not yet recruiting
Intervention Type:
Diagnostic Test
Participants:
80
Start Date:
October 1, 2020
Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma
Clinical Trial
Status:
Not yet recruiting
Intervention Type:
Drug
Participants:
40
Start Date:
October 1, 2020
Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation
Showing 1-12 of 64
Next